Status:
RECRUITING
ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy
Lead Sponsor:
Stiftung Swiss Tumor Institute
Collaborating Sponsors:
Klinik Hirslanden, Zurich
Palleos Healthcare GmbH
Conditions:
Patient Reported Outcome Measures
CAR T-Cell Therapy
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed as a feasibility study implementing electronic Patient Reported Outcomes (ePRO) in CAR T treatment for hematological malignancies, in order to describe AE reporting. ePRO assess...
Eligibility Criteria
Inclusion
- Signed ICF
- Patients \> 18 years
- Patients receiving CAR T cell treatment
- Personal smartphone with iOS or Android system. The operating system must be updated to one of the two newest main versions.
Exclusion
- Patients, whose compliance to the studies' protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted.
- Patients with insufficient knowledge about the use of a smartphone.
Key Trial Info
Start Date :
March 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2025
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT05354973
Start Date
March 21 2022
End Date
April 30 2025
Last Update
April 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinik für Hämatologie und Onkologie
Zurich, Switzerland, 8032